Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

BMS acquires Celgene for an equity value of $74bn

pharmaceutical-technologyJanuary 04, 2019

Tag: BMS , Celgene , acquisition , merger

PharmaSources Customer Service